R&D Day: Why C5a - Terminal Complement Target Deep Dive & KOL Perspective on HS and IFX-1

Prof. Niels Riedemann and Prof. Renfeng Guo and the InflaRx management team will share their in-depth complement research experience and address new insight in terminal complement activation mechanisms , their choice of the key target C5a over its receptors, and the development of InflaRx's breakthrough anti-C5a monoclonal antibody technology.